No connection

Search Results

QUCY vs XTLB

QUCY
Mainz Biomed N.V.
BEARISH
Price
$0.49
Market Cap
$6.1M
Sector
Healthcare
AI Confidence
95%
XTLB
XTL Biopharmaceuticals Ltd.
BEARISH
Price
$2.44
Market Cap
$5.8M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
QUCY
--
XTLB
--
Forward P/E
QUCY
--
XTLB
--
P/B Ratio
QUCY
7.38
XTLB
--
P/S Ratio
QUCY
11.35
XTLB
5.98
EV/EBITDA
QUCY
-0.6
XTLB
--

Profitability

Gross Margin
QUCY
72.58%
XTLB
-232.85%
Operating Margin
QUCY
-2159.86%
XTLB
-853.58%
Profit Margin
QUCY
0.0%
XTLB
0.0%
ROE
QUCY
-488.32%
XTLB
-577.13%
ROA
QUCY
-89.61%
XTLB
-240.56%

Growth

Revenue Growth
QUCY
-32.9%
XTLB
--
Earnings Growth
QUCY
--
XTLB
--

Financial Health

Debt/Equity
QUCY
4.01
XTLB
--
Current Ratio
QUCY
0.5
XTLB
0.7
Quick Ratio
QUCY
0.27
XTLB
0.46

Dividends

Dividend Yield
QUCY
--
XTLB
--
Payout Ratio
QUCY
0.0%
XTLB
0.0%

AI Verdict

QUCY BEARISH

QUCY exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis evidenced by a Current Ratio of 0.50. The company is suffering from catastrophic operational inefficiency with an operating margin of -2159.86% and a massive ROE of -488.32%. Despite beating negative earnings estimates, the fundamental trend is one of collapse, with revenue declining by 32.90% YoY and a 5-year price depreciation of 98.2%. The combination of high leverage (Debt/Equity 4.01) and shrinking revenues suggests a high risk of insolvency.

Strengths
Strong Gross Margin (72.58%) indicating product value
Recent trend of beating EPS estimates (3/4 quarters)
Positive Q/Q EPS growth (+38.5%) although still deeply negative
Risks
Severe liquidity risk with a Quick Ratio of 0.27
Extreme operational losses (Operating Margin -2159.86%)
Significant revenue contraction (-32.90% YoY)
XTLB BEARISH

XTLB exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a complete lack of positive fundamental momentum. The company suffers from catastrophic profitability metrics, including an operating margin of -853.58% and a negative gross margin of -232.85%, indicating a fundamentally broken cost structure. Liquidity is critical with a current ratio of 0.70 and a quick ratio of 0.46, suggesting an inability to meet short-term obligations. Combined with a 0/100 technical trend and an 81.5% decline over five years, the stock presents an extremely high-risk profile.

Strengths
Low current price relative to 52-week high ($10.28)
Positive EPS surprise recorded in historical 2015 data
Micro-cap status allows for high volatility spikes
Risks
Severe liquidity crisis (Current Ratio 0.70)
Extreme negative margins (Operating Margin -853.58%)
Chronic value destruction (5Y Change -81.5%)

Compare Another Pair

QUCY vs XTLB: Head-to-Head Comparison

This page compares Mainz Biomed N.V. (QUCY) and XTL Biopharmaceuticals Ltd. (XTLB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile